Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214882201> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4214882201 endingPage "677" @default.
- W4214882201 startingPage "671" @default.
- W4214882201 abstract "Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has been reported to be effective in treating conservative renal failure and renal anemia in patients undergoing dialysis. Nonetheless, its effect on posttransplant anemia (PTA) has not yet been analyzed.This study was conducted in accordance with the 1975 Declaration of Helsinki, as revised in 2013. Roxadustat was administered in 31 patients with a hemoglobin level ≤11 g/dL after renal transplant. The mean hemoglobin, serum iron, ferritin, and low-density lipoprotein (LDL) cholesterol levels and the estimated glomerular filtration rate at 4, 8, 12, 16, and 20 weeks after administration were compared with those before administration.The average (standard deviation) hemoglobin level in 25 patients (6 patients dropped out) increased from 9.8 (0.78) g/dL before administration to 12.1 (1.44) g/dL (P < .001) after 12 weeks of roxadustat administration. The mean ferritin level in patients decreased from 107.6 (84.95) ng/mL before administration to 51.7 (44.04) ng/mL (P = .022) after 8 weeks of roxadustat administration. The mean LDL cholesterol level decreased from 114.1 (31.67) mg/dL before administration to 78.7 (18.26) mg/dL (P = .0012) after 8 weeks of roxadustat administration. Complications observed in patients after roxadustat administration included reduced hemoglobin levels in 3 patients, gastrointestinal symptoms in 2 patients, and myocardial infarction in 1 patient.Hemoglobin levels significantly increased, whereas ferritin and LDL cholesterol levels significantly decreased in patients with PTA after roxadustat administration. Roxadustat seems to be an effective treatment for patients with PTA; however, the blood clotting tendency due to iron deficiency should be monitored in patients." @default.
- W4214882201 created "2022-03-05" @default.
- W4214882201 creator A5006983397 @default.
- W4214882201 creator A5058306123 @default.
- W4214882201 creator A5062053414 @default.
- W4214882201 creator A5083484049 @default.
- W4214882201 creator A5088200336 @default.
- W4214882201 date "2022-04-01" @default.
- W4214882201 modified "2023-09-26" @default.
- W4214882201 title "Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia" @default.
- W4214882201 cites W1987536739 @default.
- W4214882201 cites W2004353020 @default.
- W4214882201 cites W2034402017 @default.
- W4214882201 cites W2044068240 @default.
- W4214882201 cites W2049975126 @default.
- W4214882201 cites W2105844181 @default.
- W4214882201 cites W2146741965 @default.
- W4214882201 cites W2328140092 @default.
- W4214882201 cites W2329922226 @default.
- W4214882201 cites W2944928872 @default.
- W4214882201 cites W2963534431 @default.
- W4214882201 cites W2964045421 @default.
- W4214882201 cites W3029930991 @default.
- W4214882201 doi "https://doi.org/10.1016/j.transproceed.2022.02.004" @default.
- W4214882201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35256197" @default.
- W4214882201 hasPublicationYear "2022" @default.
- W4214882201 type Work @default.
- W4214882201 citedByCount "5" @default.
- W4214882201 countsByYear W42148822012022 @default.
- W4214882201 countsByYear W42148822012023 @default.
- W4214882201 crossrefType "journal-article" @default.
- W4214882201 hasAuthorship W4214882201A5006983397 @default.
- W4214882201 hasAuthorship W4214882201A5058306123 @default.
- W4214882201 hasAuthorship W4214882201A5062053414 @default.
- W4214882201 hasAuthorship W4214882201A5083484049 @default.
- W4214882201 hasAuthorship W4214882201A5088200336 @default.
- W4214882201 hasConcept C126322002 @default.
- W4214882201 hasConcept C126894567 @default.
- W4214882201 hasConcept C134018914 @default.
- W4214882201 hasConcept C141071460 @default.
- W4214882201 hasConcept C159641895 @default.
- W4214882201 hasConcept C2778063415 @default.
- W4214882201 hasConcept C2778248108 @default.
- W4214882201 hasConcept C2778917026 @default.
- W4214882201 hasConcept C2779056158 @default.
- W4214882201 hasConcept C71924100 @default.
- W4214882201 hasConcept C90924648 @default.
- W4214882201 hasConceptScore W4214882201C126322002 @default.
- W4214882201 hasConceptScore W4214882201C126894567 @default.
- W4214882201 hasConceptScore W4214882201C134018914 @default.
- W4214882201 hasConceptScore W4214882201C141071460 @default.
- W4214882201 hasConceptScore W4214882201C159641895 @default.
- W4214882201 hasConceptScore W4214882201C2778063415 @default.
- W4214882201 hasConceptScore W4214882201C2778248108 @default.
- W4214882201 hasConceptScore W4214882201C2778917026 @default.
- W4214882201 hasConceptScore W4214882201C2779056158 @default.
- W4214882201 hasConceptScore W4214882201C71924100 @default.
- W4214882201 hasConceptScore W4214882201C90924648 @default.
- W4214882201 hasIssue "3" @default.
- W4214882201 hasLocation W42148822011 @default.
- W4214882201 hasLocation W42148822012 @default.
- W4214882201 hasOpenAccess W4214882201 @default.
- W4214882201 hasPrimaryLocation W42148822011 @default.
- W4214882201 hasRelatedWork W113810927 @default.
- W4214882201 hasRelatedWork W1991053496 @default.
- W4214882201 hasRelatedWork W2004487628 @default.
- W4214882201 hasRelatedWork W2031351830 @default.
- W4214882201 hasRelatedWork W2050937508 @default.
- W4214882201 hasRelatedWork W2108880404 @default.
- W4214882201 hasRelatedWork W2113143771 @default.
- W4214882201 hasRelatedWork W2397445965 @default.
- W4214882201 hasRelatedWork W3154212710 @default.
- W4214882201 hasRelatedWork W40023729 @default.
- W4214882201 hasVolume "54" @default.
- W4214882201 isParatext "false" @default.
- W4214882201 isRetracted "false" @default.
- W4214882201 workType "article" @default.